PARP inhibitors in the ovarian cancer therapy

Maksymilian Artur Kruczała; Aleksandra Grela-Wojewoda; Ida Cedrych

doi:10.17772/gp/59268

Vol 87, No 2 (2016)

Review paper

View PDF (Polish)

Download PDF file

Get Citation

PARP inhibitors in the ovarian cancer therapy

Maksymilian Artur Kruczała, Aleksandra Grela-Wojewoda, Ida Cedrych

DOI: 10.17772/gp/59268

Pubmed: 27306290

Ginekol Pol 2016;87(2):131-134.

Vol 87, No 2 (2016)

REVIEW PAPERS Gynecology

Abstract

Treatment of the malignant ovarian tumors remains challenging. Some of the reasons are as follows: lack of effective screening technique, usually asymptomatic early stages of the disease, which effects in detecting the disease in advanced stage, and eventually poor prognosis. Treatment of the relapse remains palliative. Inventing new drugs – like PARP inhibitors - gives hope for improvement of the treatment outcomes. This review paper presents actual knowledge on PARP inhibitors in the ovarian cancer therapy.